Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)

Phase 1 Unknown 84 enrolled Shenzhen Kangtai Biological Products Co., LTD Beijing Minhai Biotechnology Co., Ltd · collab Hunan Provincial Center for Disease Control and Prevention · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to 17 years.

Timeline

Start: 2021-08
Primary completion: 2022-09
Completion: 2022-10

Publications

Liu J, Huang B, Li G, Huang T, Wang D, Zhang L, Deng Y, Chang X, Liu Y, Li W, Zhang S, Huang W, Tan W, Gao L. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials. Pediatr Infect Dis J. 2023 Dec 1;42(12):1136-1142. doi: 10.1097/INF.0000000000004085. Epub 2023 Sep 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SARS-CoV-2 Vaccine (Vero Cells), Inactivated	Vaccine	—	Intramuscular

Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)

Summary

Timeline

Publications

Drugs

Indications